Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents

Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area. We performed genome, and drug-res...

Full description

Saved in:

Bibliographic Details
Published in:	Antimicrobial agents and chemotherapy Vol. 66; no. 7; p. e0005322
Main Authors:	Jacobs, Samantha E, Jacobs, Jonathan L, Dennis, Emily K, Taimur, Sarah, Rana, Meenakshi, Patel, Dhruv, Gitman, Melissa, Patel, Gopi, Schaefer, Sarah, Iyer, Kishore, Moon, Jang, Adams, Victoria, Lerner, Polina, Walsh, Thomas J, Zhu, YanChun, Anower, Mohammed Rokebul, Vaidya, Mayuri M, Chaturvedi, Sudha, Chaturvedi, Vishnu
Format:	Journal Article
Language:	English
Published:	United States 19.07.2022
Subjects:	Antifungal Agents - pharmacology Candida auris Drug Resistance, Fungal - genetics Humans Microbial Sensitivity Tests Phylogeny Candida auris New York flucytosine gene mutation whole-genome sequencing amphotericin B real-time PCR transplant patient antifungal combination caspofungin gene deletion multidrug-resistant fluconazole echinocandins pan-drug-resistant
ISSN:	1098-6596, 1098-6596
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area. We performed genome, and drug-resistance analysis of C. auris isolates from a patient who underwent multi-visceral transplantation. Whole-genome comparisons of 19 isolates, collected over 72 days, revealed closed similarity (Average Nucleotide Identity > 0.9996; Aligned Percentage > 0.9764) and a distinct subcluster of NY C. auris South Asia Clade I. All isolates had azole-linked resistance in (K143R) and (V704L). Echinocandin resistance first appeared with (S639Y) mutation and then a unique (F635C) mutation. Flucytosine-resistant isolates had mutations in , , and . Two pan-drug-resistant C. auris isolates had uracil phosphoribosyltransferase deletion ( [1 33]) and the elimination of expression, confirmed by a qPCR test developed in this study. Besides mutations, four amphotericin B-resistant isolates showed no distinct nonsynonymous variants suggesting unknown genetic elements driving the resistance. Pan-drug-resistant C. auris isolates were not susceptible to two-drug antifungal combinations tested by checkerboard, Etest, and time-kill methods. The fungal population pattern, discerned from SNP phylogenetic analysis, was consistent with in-hospital or inpatient evolution of C. auris isolates circulating locally and not indicative of a recent introduction from elsewhere. The emergence of pan-drug-resistance to four major classes of antifungals in C. auris is alarming. Patients at high risk for drug-resistant C. auris might require novel therapeutic strategies and targeted pre-and/or posttransplant surveillance.
AbstractList	Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area. We performed genome, and drug-resistance analysis of C. auris isolates from a patient who underwent multi-visceral transplantation. Whole-genome comparisons of 19 isolates, collected over 72 days, revealed closed similarity (Average Nucleotide Identity > 0.9996; Aligned Percentage > 0.9764) and a distinct subcluster of NY C. auris South Asia Clade I. All isolates had azole-linked resistance in ERG11(K143R) and CDR1(V704L). Echinocandin resistance first appeared with FKS1(S639Y) mutation and then a unique FKS1(F635C) mutation. Flucytosine-resistant isolates had mutations in FCY1, FUR1, and ADE17. Two pan-drug-resistant C. auris isolates had uracil phosphoribosyltransferase deletion (FUR1[1Δ33]) and the elimination of FUR1 expression, confirmed by a qPCR test developed in this study. Besides ERG11 mutations, four amphotericin B-resistant isolates showed no distinct nonsynonymous variants suggesting unknown genetic elements driving the resistance. Pan-drug-resistant C. auris isolates were not susceptible to two-drug antifungal combinations tested by checkerboard, Etest, and time-kill methods. The fungal population pattern, discerned from SNP phylogenetic analysis, was consistent with in-hospital or inpatient evolution of C. auris isolates circulating locally and not indicative of a recent introduction from elsewhere. The emergence of pan-drug-resistance to four major classes of antifungals in C. auris is alarming. Patients at high risk for drug-resistant C. auris might require novel therapeutic strategies and targeted pre-and/or posttransplant surveillance.Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area. We performed genome, and drug-resistance analysis of C. auris isolates from a patient who underwent multi-visceral transplantation. Whole-genome comparisons of 19 isolates, collected over 72 days, revealed closed similarity (Average Nucleotide Identity > 0.9996; Aligned Percentage > 0.9764) and a distinct subcluster of NY C. auris South Asia Clade I. All isolates had azole-linked resistance in ERG11(K143R) and CDR1(V704L). Echinocandin resistance first appeared with FKS1(S639Y) mutation and then a unique FKS1(F635C) mutation. Flucytosine-resistant isolates had mutations in FCY1, FUR1, and ADE17. Two pan-drug-resistant C. auris isolates had uracil phosphoribosyltransferase deletion (FUR1[1Δ33]) and the elimination of FUR1 expression, confirmed by a qPCR test developed in this study. Besides ERG11 mutations, four amphotericin B-resistant isolates showed no distinct nonsynonymous variants suggesting unknown genetic elements driving the resistance. Pan-drug-resistant C. auris isolates were not susceptible to two-drug antifungal combinations tested by checkerboard, Etest, and time-kill methods. The fungal population pattern, discerned from SNP phylogenetic analysis, was consistent with in-hospital or inpatient evolution of C. auris isolates circulating locally and not indicative of a recent introduction from elsewhere. The emergence of pan-drug-resistance to four major classes of antifungals in C. auris is alarming. Patients at high risk for drug-resistant C. auris might require novel therapeutic strategies and targeted pre-and/or posttransplant surveillance. Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area. We performed genome, and drug-resistance analysis of C. auris isolates from a patient who underwent multi-visceral transplantation. Whole-genome comparisons of 19 isolates, collected over 72 days, revealed closed similarity (Average Nucleotide Identity > 0.9996; Aligned Percentage > 0.9764) and a distinct subcluster of NY C. auris South Asia Clade I. All isolates had azole-linked resistance in (K143R) and (V704L). Echinocandin resistance first appeared with (S639Y) mutation and then a unique (F635C) mutation. Flucytosine-resistant isolates had mutations in , , and . Two pan-drug-resistant C. auris isolates had uracil phosphoribosyltransferase deletion ( [1 33]) and the elimination of expression, confirmed by a qPCR test developed in this study. Besides mutations, four amphotericin B-resistant isolates showed no distinct nonsynonymous variants suggesting unknown genetic elements driving the resistance. Pan-drug-resistant C. auris isolates were not susceptible to two-drug antifungal combinations tested by checkerboard, Etest, and time-kill methods. The fungal population pattern, discerned from SNP phylogenetic analysis, was consistent with in-hospital or inpatient evolution of C. auris isolates circulating locally and not indicative of a recent introduction from elsewhere. The emergence of pan-drug-resistance to four major classes of antifungals in C. auris is alarming. Patients at high risk for drug-resistant C. auris might require novel therapeutic strategies and targeted pre-and/or posttransplant surveillance.
Author	Gitman, Melissa Patel, Gopi Schaefer, Sarah Chaturvedi, Vishnu Moon, Jang Iyer, Kishore Lerner, Polina Taimur, Sarah Adams, Victoria Jacobs, Samantha E Jacobs, Jonathan L Rana, Meenakshi Chaturvedi, Sudha Vaidya, Mayuri M Patel, Dhruv Dennis, Emily K Zhu, YanChun Anower, Mohammed Rokebul Walsh, Thomas J
Author_xml	– sequence: 1 givenname: Samantha E orcidid: 0000-0002-9770-886X surname: Jacobs fullname: Jacobs, Samantha E organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 2 givenname: Jonathan L orcidid: 0000-0001-5608-4256 surname: Jacobs fullname: Jacobs, Jonathan L organization: American Type Culture Collection, Manassas, Virginia, USA – sequence: 3 givenname: Emily K orcidid: 0000-0001-7928-9705 surname: Dennis fullname: Dennis, Emily K organization: Wadsworth Center New York State Department of Health, Albany, New York, USA – sequence: 4 givenname: Sarah surname: Taimur fullname: Taimur, Sarah organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 5 givenname: Meenakshi surname: Rana fullname: Rana, Meenakshi organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 6 givenname: Dhruv surname: Patel fullname: Patel, Dhruv organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 7 givenname: Melissa orcidid: 0000-0002-6960-0763 surname: Gitman fullname: Gitman, Melissa organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 8 givenname: Gopi surname: Patel fullname: Patel, Gopi organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 9 givenname: Sarah surname: Schaefer fullname: Schaefer, Sarah organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 10 givenname: Kishore surname: Iyer fullname: Iyer, Kishore organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 11 givenname: Jang surname: Moon fullname: Moon, Jang organization: Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA – sequence: 12 givenname: Victoria surname: Adams fullname: Adams, Victoria organization: Mount Sinai Hospital, New York, New York, USA – sequence: 13 givenname: Polina surname: Lerner fullname: Lerner, Polina organization: Mount Sinai Hospital, New York, New York, USA – sequence: 14 givenname: Thomas J orcidid: 0000-0002-4142-8711 surname: Walsh fullname: Walsh, Thomas J organization: Weill Cornell Medicine of Cornell University, New York, New York, USA – sequence: 15 givenname: YanChun surname: Zhu fullname: Zhu, YanChun organization: Wadsworth Center New York State Department of Health, Albany, New York, USA – sequence: 16 givenname: Mohammed Rokebul surname: Anower fullname: Anower, Mohammed Rokebul organization: Wadsworth Center New York State Department of Health, Albany, New York, USA – sequence: 17 givenname: Mayuri M surname: Vaidya fullname: Vaidya, Mayuri M organization: Wadsworth Center New York State Department of Health, Albany, New York, USA – sequence: 18 givenname: Sudha orcidid: 0000-0003-0906-8426 surname: Chaturvedi fullname: Chaturvedi, Sudha organization: Wadsworth Center New York State Department of Health, Albany, New York, USA – sequence: 19 givenname: Vishnu orcidid: 0000-0002-3922-9676 surname: Chaturvedi fullname: Chaturvedi, Vishnu organization: Wadsworth Center New York State Department of Health, Albany, New York, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35770999$$D View this record in MEDLINE/PubMed
BookMark	eNpNj0tLAzEYRYNU7EN3riVLN6lJpnkty9iqUFBE18M3maSMTDN1kiz89x2wgqt7Lhwu3DmahD44hG4ZXTLG9QOAXVJKRUE4v0AzRo0mUhg5-cdTNI_xa7TGQq_QtBBKUWPMDG1KCE3bAIY8tBG_QSCPQ96TdxfbmCAknHq87fOAyw5idBH3Hq9Dan0Oe-jweu9Citfo0kMX3c05F-hzu_kon8nu9emlXO8IrPQqkUIwB1baGmoQ0inGobDaF8IDqwX3XFivpRGcUQeee1FDoZVWkitjJTR8ge5_d49D_51dTNWhjdZ1HQTX51hxqbnSkkkzqndnNdcH11THoT3A8FP9Xecno8tb2w
CitedBy_id	crossref_primary_10_1007_s15010_024_02378_8 crossref_primary_10_1186_s12866_024_03334_0 crossref_primary_10_3390_w16070936 crossref_primary_10_1128_aac_00955_23 crossref_primary_10_3389_fmicb_2023_1160196 crossref_primary_10_1080_22221751_2024_2377584 crossref_primary_10_1038_s41598_025_15302_3 crossref_primary_10_1080_08927014_2024_2396020 crossref_primary_10_3390_jof10070477 crossref_primary_10_1007_s00284_023_03416_8 crossref_primary_10_1016_j_crmicr_2025_100354 crossref_primary_10_3390_jof9040430 crossref_primary_10_3389_fmicb_2024_1439273 crossref_primary_10_1093_ofid_ofae072 crossref_primary_10_1017_ice_2025_10217 crossref_primary_10_1016_j_ijantimicag_2023_106906 crossref_primary_10_3390_jof11060406 crossref_primary_10_3390_jof10060392 crossref_primary_10_1128_jcm_00399_25 crossref_primary_10_3390_jof9080849 crossref_primary_10_1093_jac_dkad303 crossref_primary_10_1080_14787210_2025_2505567 crossref_primary_10_3390_pharmaceutics16070957 crossref_primary_10_1016_j_celrep_2023_112522 crossref_primary_10_1080_22221751_2024_2322649 crossref_primary_10_1016_j_ijantimicag_2023_106819 crossref_primary_10_1128_spectrum_02659_24 crossref_primary_10_1128_cmr_00142_23 crossref_primary_10_3390_jof8090946 crossref_primary_10_3390_antibiotics12020220 crossref_primary_10_1128_jcm_00043_25 crossref_primary_10_1016_j_nmni_2024_101444 crossref_primary_10_3390_jof10040285 crossref_primary_10_1128_jcm_01767_22 crossref_primary_10_1128_aac_00556_24 crossref_primary_10_1556_030_2025_02615 crossref_primary_10_3390_antibiotics12050884 crossref_primary_10_1111_apm_13336 crossref_primary_10_1128_mbio_02303_24 crossref_primary_10_1099_jmm_0_001835 crossref_primary_10_1080_14787210_2023_2240956 crossref_primary_10_1128_jcm_00525_24 crossref_primary_10_1038_s41586_025_08678_9 crossref_primary_10_3389_ffunb_2023_1061150 crossref_primary_10_1016_j_cej_2025_166070 crossref_primary_10_3389_fmicb_2025_1575755 crossref_primary_10_1128_aem_02406_24 crossref_primary_10_1128_aac_00601_25 crossref_primary_10_1097_QCO_0000000000001032 crossref_primary_10_3389_fimmu_2025_1596283 crossref_primary_10_1128_spectrum_02942_23 crossref_primary_10_1007_s11101_025_10093_x crossref_primary_10_1007_s11046_025_00974_2 crossref_primary_10_1128_jcm_01528_23 crossref_primary_10_1016_j_micres_2024_127797 crossref_primary_10_1007_s42770_023_01239_0 crossref_primary_10_1007_s11046_024_00832_7 crossref_primary_10_1371_journal_ppat_1012559 crossref_primary_10_3390_jof11060445 crossref_primary_10_3390_stresses4040041 crossref_primary_10_1128_aac_00081_23 crossref_primary_10_1128_aac_00381_24 crossref_primary_10_1016_j_jhin_2023_10_017 crossref_primary_10_1073_pnas_2314087121 crossref_primary_10_1016_j_cmi_2024_10_010 crossref_primary_10_3389_fcimb_2025_1641373 crossref_primary_10_3390_pathogens14090903 crossref_primary_10_1128_spectrum_03540_23 crossref_primary_10_1093_mmy_myae056 crossref_primary_10_3390_antibiotics11111601 crossref_primary_10_1016_j_cll_2024_10_005 crossref_primary_10_1128_spectrum_02809_24 crossref_primary_10_1093_jac_dkaf241 crossref_primary_10_1371_journal_pone_0326200 crossref_primary_10_3390_jof9060663 crossref_primary_10_1016_j_micinf_2023_105234 crossref_primary_10_3390_pathogens14060588 crossref_primary_10_1007_s40475_024_00338_8 crossref_primary_10_1016_j_jiac_2023_03_018 crossref_primary_10_1128_aac_00911_24 crossref_primary_10_1016_j_apsb_2025_06_013 crossref_primary_10_3389_fcimb_2025_1610743 crossref_primary_10_3390_jof9020168 crossref_primary_10_1128_aac_01243_22 crossref_primary_10_1128_msphere_00270_25 crossref_primary_10_1093_jambio_lxaf170 crossref_primary_10_1016_j_cmi_2023_04_025 crossref_primary_10_1016_j_micpath_2025_107930 crossref_primary_10_3390_microorganisms12050927 crossref_primary_10_1016_j_drudis_2023_103596 crossref_primary_10_1093_ofid_ofae257 crossref_primary_10_3389_fpubh_2023_1244358 crossref_primary_10_3390_jof9020176 crossref_primary_10_1093_jac_dkae415 crossref_primary_10_1128_msphere_00977_24 crossref_primary_10_1038_s44259_025_00093_4 crossref_primary_10_3390_jcm12051912 crossref_primary_10_1128_aac_01265_24
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/aac.00053-22
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology Pharmacy, Therapeutics, & Pharmacology
EISSN	1098-6596
ExternalDocumentID	35770999
Genre	Research Support, U.S. Gov't, P.H.S Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: R21 AI156573 – fundername: NCEZID CDC HHS grantid: U50 CK000423 – fundername: HHS \| National Institutes of Health (NIH) grantid: 1R21AI156573-01A1 – fundername: HHS \| Centers for Disease Control and Prevention (CDC) grantid: NU50CK000423
GroupedDBID	--- .55 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CS3 CUY CVF DIK E3Z EBS ECM EIF F5P FRP GX1 H13 HH5 HYE HZ~ H~9 K-O KQ8 L7B LSO NPM O9- OK1 P2P RHI RNS RPM RSF TR2 UHB W2D W8F WH7 WOQ X7M 7X8 AAGFI
ID	FETCH-LOGICAL-a484t-351eac6cbaba56e712a3c8f35fa1b52f25cf8695210eaf2f5ba387876279c6ad2
IEDL.DBID	7X8
ISICitedReferencesCount	120
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00053-22&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-6596
IngestDate	Fri Sep 05 06:20:08 EDT 2025 Thu Apr 03 07:10:56 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	Candida auris New York flucytosine gene mutation whole-genome sequencing amphotericin B real-time PCR transplant patient antifungal combination caspofungin gene deletion multidrug-resistant fluconazole echinocandins pan-drug-resistant
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a484t-351eac6cbaba56e712a3c8f35fa1b52f25cf8695210eaf2f5ba387876279c6ad2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0001-7928-9705 0000-0003-0906-8426 0000-0002-3922-9676 0000-0002-4142-8711 0000-0001-5608-4256 0000-0002-6960-0763 0000-0002-9770-886X
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/9295560
PMID	35770999
PQID	2682786169
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2682786169 pubmed_primary_35770999
PublicationCentury	2000
PublicationDate	2022-07-19
PublicationDateYYYYMMDD	2022-07-19
PublicationDate_xml	– month: 07 year: 2022 text: 2022-07-19 day: 19
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Antimicrobial agents and chemotherapy
PublicationTitleAlternate	Antimicrob Agents Chemother
PublicationYear	2022
SSID	ssj0006590
Score	2.658621
Snippet	Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	e0005322
SubjectTerms	Antifungal Agents - pharmacology Candida auris Drug Resistance, Fungal - genetics Humans Microbial Sensitivity Tests Phylogeny
Title	Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents
URI	https://www.ncbi.nlm.nih.gov/pubmed/35770999 https://www.proquest.com/docview/2682786169
Volume	66
WOSCitedRecordID	wos00053-22&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5848XH-n4RQTwZdps2r5OIunjQpYjK3pY0TcRLq3YV9t-babvsSRC8lF5Kh2QymWTm-z6As8hxpb3TNDbKU1Q5oiqSGU0yl1htuRI1E9PLvRwM1HCo0_bCrWrbKqcxsQ7UeWnxjrzLhGJSiUjoy_cPiqpRWF1tJTTmYTEOqQy2dMnhjC1ccN2wEWhFw7uYNr4z1TXB2hqISlE297fkst5k-uv_NW8D1tr0klw1_rAJc67owHIjODnpwMpDW0rvwHnakFZPLsjTDINVXZBzks7orCdbcHuNyJfcECQgqkhqCnrz-fVKH12FuWcxJuOS9MOPSS2w6SpSenKFPUghjqAtCN6qtuG5f_t0fUdb8QVqEpWMscM_xGRhM5MZLpyMmImt8jH3Jso484xbr4QOu3_PGc88z0ysJMZWqa0wOduBhaIs3B4QF6HKeuKlFiyxQis8hhrver08Dy4S78PpdExHwbmxYmEKV35Vo9mo7sNuMzGj94aFYxRzKTG9PfjD14ewyhC2gISY-ggWfVja7hiW7Pf4rfo8qb0mPAfpww_LQ8tG
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Candida+auris+Pan-Drug-Resistant+to+Four+Classes+of+Antifungal+Agents&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Jacobs%2C+Samantha+E&rft.au=Jacobs%2C+Jonathan+L&rft.au=Dennis%2C+Emily+K&rft.au=Taimur%2C+Sarah&rft.date=2022-07-19&rft.issn=1098-6596&rft.eissn=1098-6596&rft.volume=66&rft.issue=7&rft.spage=e0005322&rft_id=info:doi/10.1128%2Faac.00053-22&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-6596&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-6596&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-6596&client=summon